2026-2034年肝腎症候群治療全球市場規模、佔有率、趨勢和成長分析報告

預計肝腎症候群治療市場規模將從 2025 年的 225.6 億美元成長到 2034 年的 408.5 億美元，2026 年至 2034 年的複合年成長率為 6.82%。

隨著醫療保健領域對嚴重肝臟併發症的認知不斷提高，全球肝腎症候群（HSS）治療市場正在不斷擴大。 HSS是一種危及生命的疾病，發生於晚期肝病患者，最終導致腎衰竭。有效的治療對於提高患者存活率和控制肝病相關併發症至關重要。

市場的主要促進因素包括肝硬化和慢性肝炎等肝臟疾病的日益普遍。醫療保健意識的提高和診斷能力的進步使得肝腎症候群的早期發現和治療成為可能。此外，藥物研發正致力於開發能夠改善腎功能並穩定等待肝臟移植患者病情的藥物。

未來，隨著全球醫學研究的進步和醫療基礎設施的完善，肝腎綜合症治療市場預計將持續成長。創新藥物療法和輔助治療的研發將提升患者照護。此外，對肝病研發和專科醫療設施投入的增加，也將進一步推動未來幾年的市場成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球肝腎症候群治療市場：依治療方式分類

• 市場分析、洞察與預測
• 治療方法A（Terribaz、Glypressin、Lucasin、Hepatren）
• 外科治療A（肝臟移植、外科分流、腎臟替代療法等）

第5章：全球肝腎症候群治療市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院和診所
• 門診手術中心
• 學術研究機構
• 其他

第6章 全球肝腎症候群治療市場：依類型分類

• 市場分析、洞察與預測
• 1型肝腎綜合症
• 2型肝腎綜合症

第7章 全球肝腎症候群治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Cumberland Pharmaceuticals Inc
  • Orphan Therapeutics LLC
  • BioVie Inc
  • Mallinckrodt Pharmaceuticals
  • Ikaria Inc
  • ESP Pharma Inc
  • Edwards Lifesciences Corporation
  • Becton, Dickinson And Company
  • Fuji Systems Corp
  • Johnson & Johnson Co

The Hepatorenal Syndrome Treatment Market size is expected to reach USD 40.85 Billion in 2034 from USD 22.56 Billion (2025) growing at a CAGR of 6.82% during 2026-2034.

The global hepatorenal syndrome treatment market has grown as awareness of severe liver-related complications increases within the healthcare sector. Hepatorenal syndrome is a life-threatening condition that occurs in patients with advanced liver disease, leading to kidney failure. Effective treatment is essential for improving patient survival and managing complications associated with liver disorders.

Key drivers of the market include the increasing prevalence of liver diseases such as cirrhosis and chronic hepatitis. Growing healthcare awareness and improvements in diagnostic capabilities are enabling earlier detection and treatment of hepatorenal syndrome. Additionally, pharmaceutical research is focusing on developing medications that improve kidney function and stabilize patients awaiting liver transplantation.

In the future, the hepatorenal syndrome treatment market is expected to grow as medical research advances and healthcare infrastructure improves worldwide. The development of innovative drug therapies and supportive treatment options will enhance patient care. Increasing investments in liver disease research and specialized healthcare facilities will further support market expansion in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment

• TherapeuticsA (Terlivaz, Glypressin, Lucassin, Hepatoren)
• Surgical TreatmentA (Liver Transplantation, Surgical Shunting, Renal Replacement Therapy, Others)

By End-users

• Hospitals and Clinics
• Ambulatory Surgical centers
• Academic Research Institutes
• Others

By Type

• Type 1 Hepatorenal Syndrome
• Type 2 Hepatorenal Syndrome

COMPANIES PROFILED

• Cumberland Pharmaceuticals Inc, Orphan Therapeutics LLC, BioVie Inc, Mallinckrodt Pharmaceuticals, Ikaria Inc, ESP Pharma Inc, Edwards Lifesciences Corporation, Becton, Dickinson and Company, Fuji Systems Corp, Johnson Johnson Co
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. TherapeuticsA (Terlivaz, Glypressin, Lucassin, Hepatoren) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Surgical TreatmentA (Liver Transplantation, Surgical Shunting, Renal Replacement Therapy, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET: BY END-USERS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-users
• 5.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Ambulatory Surgical centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Academic Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Type
• 6.2. Type 1 Hepatorenal Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Type 2 Hepatorenal Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Treatment
  • 7.2.2 By End-users
  • 7.2.3 By Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Treatment
  • 7.3.2 By End-users
  • 7.3.3 By Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Treatment
  • 7.4.2 By End-users
  • 7.4.3 By Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Treatment
  • 7.5.2 By End-users
  • 7.5.3 By Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Treatment
  • 7.6.2 By End-users
  • 7.6.3 By Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HEPATORENAL SYNDROME TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Cumberland Pharmaceuticals Inc
  • 9.2.2 Orphan Therapeutics LLC
  • 9.2.3 BioVie Inc
  • 9.2.4 Mallinckrodt Pharmaceuticals
  • 9.2.5 Ikaria Inc
  • 9.2.6 ESP Pharma Inc
  • 9.2.7 Edwards Lifesciences Corporation
  • 9.2.8 Becton, Dickinson And Company
  • 9.2.9 Fuji Systems Corp
  • 9.2.10 Johnson & Johnson Co